Everything below concerns Plasma half-life. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
the side lengths a, b, and c; the semiperimeter s = a + b + c/2 (half the perimeter p); the angle measures A, B, and C of the angles of the vertices opposite the respective sides a, b, and c (with the vertices denoted with the same symbols as their angle measures); the values of trigonometric functions of the angles; the area T of the triangle; the medians ma, mb, and mc of the sides (each being the length of the line segment from the midpoint of the side to the opposite vertex); the altitudes ha, hb, and hc (each being the length of a segment perpendicular to one side and reaching from that side (or possibly the extension of that side) to the opposite vertex); the lengths of the internal angle bisectors ta, tb, and tc (each being a segment from a vertex to the opposite side and bisecting the vertex's angle); the perpendicular bisectors pa, pb, and pc of the sides (each being the length of a segment perpendicular to one side at its midpoint and reaching to one of the other sides); the lengths of line segments with an endpoint at an arbitrary point P in the plane (for example, the length of the segment from P to vertex A is denoted PA or AP); the inradius r (radius of the circle inscribed in the triangle, tangent to all three sides), the exradii ra, rb, and rc (each being the radius of an excircle tangent to side a, b, or c respectively and tangent to the extensions of the other two sides), and the circumradius R (radius of the circle circumscribed around the triangle and passing through all three vertices).
== Delivery vehicles == There are different types of drug delivery vehicles, such as polymeric micelles, liposomes, lipoprotein-based drug carriers, nano-particle drug carriers, dendrimers, etc. An ideal drug delivery vehicle must be non-toxic, biocompatible, non-immunogenic, biodegradable, and must avoid recognition by the host's defense mechanisms[3].
When the duty cycle is increased to d = 0.60 the range of completely stable q values decreases (see Fig 3 (b)) as indicated by the reduction of green that the horizontal line intersects. In this representation the total range of stable q values along the x-axis, that is defined by the intersection of the line through the blue and green regions, is greater than the total range of stable q values along the y-axis that is defined by the intersection of the line through the yellow and green regions. In Fig 3 (b) the overall stability of the linear DIT in the y direction is smaller than in the x direction. If the frequency of the linear DIT is decreased to cause a particular ion to have a q value that corresponds to right hand side boundary of the completely stable green region, then it will excite and ultimately eject in the y direction. This is the fundamental mechanism that allows control over the direction of ion excitation in a linear DIT without resonant excitation.
=== Season 2 === Season 2 opens with Radhi adjusting to life outside the hospital after stepping away from her duties, while Reena struggles under the new leadership of Arjun, the recently appointed CEO. Encouraged by her children and her own sense of purpose, Radhi reclaims her role. The story follows Radhi and Reena dealing with their past, fuelled by the arrival of Reena's biological father and Radhi's past love interest, Dr. Vijay. Soon, both Reena and Vijay get to know the truth about each other but very soon the former meets with an accident.
Due to its extremely long half-life, 209Bi can be treated as non-radioactive for nearly all applications. It is much less radioactive than human flesh, so it poses no real radiation hazard. Though 209Bi holds the half-life record for alpha decay, it does not have the longest known half-life of any nuclide; this distinction belongs to tellurium-128 (128Te) with a half-life estimated at 7.7×1024 years by double beta decay. The half-life of 209Bi was confirmed in 2012 by an Italian team in Gran Sasso who reported (2.01±0.08)×1019 years. They also reported an even longer partial half-life for alpha decay of 209Bi to the first excited state of 205Tl (at 204 keV), estimated at 1.66×1021 years. Even though this value is shorter than the half-life of 128Te, both alpha decays of 209Bi hold the record of the thinnest natural line widths of any measurable physical excitation, estimated respectively at ΔΕ ≈ 5.5×10−43 eV and ΔΕ ≈ 1.3×10−44 eV in application of the uncertainty principle
Sources: en.wikipedia.org
In November 2025, YouTube terminated Peters' original channel for facilitating access to websites selling regulated goods, canceling two additional channels in April 2026 for "severe or repeated violations." Although he attempted to return to the platform with other channels, YouTube permanently terminated these accounts in April 2026, citing a violation of its terms of service regarding ban evasion. A November 2025 video of him injecting his then 17-year-old girlfriend with fat-dissolving peptides to reshape her jaw gained attention online. In a later stream, he injected influencer Jenny Popach with Aqualyx, a fat-dissolving acid. On December 27, 2025, Peters appeared in an interview with conservative political commentator Michael Knowles for The Daily Wire. In it, Peters described Vice President JD Vance as "subhuman" for his "recessed side profile" and for being "obese", asking, "How are you fat and expected to lead a country?" He agreed with Knowles's criticism of California governor Gavin Newsom as both a "degenerate" and a "liar" but said that, in a potential 2028 United States presidential election in which Newsom ran against Vance, he would vote for "Chad" Newsom for "mogging" (being more attractive than) Vance. The segment soon went viral online. Other clips of him from the interview, including one in which he described actress Sydney Sweeney as "malformed" with an "extremely recessed" upper maxilla and "eyes of doom with no infraorbital support", also went viral online.
== Contraindications == Nicotine use for tobacco cessation has few contraindications. It is not known whether nicotine replacement therapy is effective for smoking cessation in adolescents, as of 2014. It is therefore not recommended to adolescents. It is not safe to use nicotine during pregnancy or breastfeeding, although it is safer than smoking. The desirability of NRT use in pregnancy is therefore debated. Randomized trials and observational studies of nicotine replacement therapy in cardiovascular patients show no increase in adverse cardiovascular events compared to those treated with placebo. Using nicotine products during cancer treatment may be contraindicated, as nicotine may promote tumour growth, but temporary use of NRTs to quit smoking may be advised for harm reduction. Nicotine gum is contraindicated in individuals with temporomandibular joint disease. People with chronic nasal disorders and severe reactive airway disease require additional precautions when using nicotine nasal sprays. Nicotine in any form is contraindicated in individuals with a known hypersensitivity to nicotine.
== Development == Dermal macrophages are either from embryonic progenitors or circulating progenitors. Numerous dermal macrophages are present in the skin at birth due to the infiltration of yolk-sac derived macrophages and haematopoietic stem cell (HSC)-derived monocytes. The prenatal population of dermal macrophages is gradually replaced by the recruitment and differentiation of circulating progenitors in adulthood. Prenatal dermal macrophages are not to be confused with Langerhans cells as they uniquely express CD14 and FXIIIa and lack CD1a.
A 2022 study concluded that the practice of rinsing uncooked chicken actually increases the risk of pathogen transfer through the splashing of water droplets, with factors such as faucet height, flow type, and surface stiffness affecting the risk of cross-contamination. The most common bacterial foodborne pathogens are:
where a0 is the average intermolecular distance of the molecule that is freezing within the liquid, d is the overall thickness of the liquid film, η is the solution viscosity, R is the particle radius and z is an exponent that can vary from 1 to 5. As expected, vc decreases as particle radius R goes up.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.